Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to -$3.5 million.

  • Syndax Pharmaceuticals' Change in Account Payables rose 4712.14% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 87567.33%. This contributed to the annual value of $1.7 million for FY2024, which is 7032.61% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Change in Account Payables stood at -$3.5 million for Q3 2025, which was up 4712.14% from $7.3 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Change in Account Payables high stood at $7.3 million for Q2 2025, and its period low was -$6.7 million during Q3 2024.
  • Its 5-year average for Change in Account Payables is $543052.6, with a median of $676000.0 in 2022.
  • In the last 5 years, Syndax Pharmaceuticals' Change in Account Payables surged by 26676.83% in 2021 and then tumbled by 82928.99% in 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Account Payables (Quarter) stood at $547000.0 in 2021, then crashed by 605.3% to -$2.8 million in 2022, then soared by 241.53% to $3.9 million in 2023, then skyrocketed by 71.98% to $6.7 million in 2024, then tumbled by 152.42% to -$3.5 million in 2025.
  • Its last three reported values are -$3.5 million in Q3 2025, $7.3 million for Q2 2025, and -$1.6 million during Q1 2025.